Filing Flows › Niagen Bioscience (NAGE) › Guidance & outlook
Niagen Bioscience (NAGE) guidance and outlook
Niagen Bioscience (NAGE) gave its guidance on Nov 4, 2026: Revenue (segment) +15% to +20% for FY2026. Niagen Bioscience's 10-Q filed Nov 4, 2026 makes 15 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | +15% to +20% | new |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- We will have early access to the premises starting on December 1, 2026, prior to the commencement date for move-in and related activities.
- This change is expected to further concentrate our revenue mix toward higher-growth, consumer-oriented product offerings and ingredient sales.
- We may also undertake organizational and workforce adjustments in response to the divestiture; however, any related cost savings are expected to be realized over time and not immediately.
- The exit of this operating segment is expected to reduce ongoing operating complexity and may result in greater margin consistency across our remaining operations over time.
- Accordingly, we do not expect to recognize any further net sales and cost of sales from this TSA in future periods.
- We may, however, seek additional capital in the next twelve months, both to meet our projected operating plans after the next twelve months and/or to fund our longer-term strategic objectives.
- As a result of the divestiture, we do not expect to generate additional net sales from this segment in future periods.
- Accordingly, we do not expect to recognize additional related revenue in future periods.
- We do not expect this segment to generate additional net sales or incur additional cost of sales in future periods.
- Accordingly, we do not expect to incur additional related cost of sales in future periods.
- We expect R&D spending within these segments to continue to vary based on the timing and scope of research projects, clinical development activities, scientific engagement initiatives, and internal resource allocation.
- Our future capital requirements will be influenced by several factors, including cash flows from operations, sales growth, gross margin performance, planned investments in research and development and commercialization activities, and the timing and scale of potential strategic initiatives.
Niagen Bioscience's latest quarter
Niagen Bioscience, Q3 2026: revenue $27.2M (-20% year over year), operating margin -5.8%, net loss $1.2M, operating cash flow $2.6M. The chart follows the revenue to costs, profit and cash.
Questions
Did Niagen Bioscience raise or lower its guidance?
Niagen Bioscience (NAGE) gave its guidance on Nov 4, 2026: Revenue (segment) +15% to +20% for FY2026.
What does Niagen Bioscience expect?
We will have early access to the premises starting on December 1, 2026, prior to the commencement date for move-in and related activities. This change is expected to further concentrate our revenue mix toward higher-growth, consumer-oriented product offerings and ingredient sales. We may also undertake organizational and workforce adjustments in response to the divestiture; however, any related cost savings are expected to be realized over time and not immediately.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.